Biogen’s Power Vacuum and Alzheimer’s Trial Fuels M&A Talk

  • Shares drop in early New York trading after 9% gain Tuesday
  • With CEO leaving, company puts up “short-term ‘for sale’ sign”

On July 21, as Biogen Inc. Chief Executive Officer George Scangos announced he would step down, he floated the idea that his company might buy rivals to cement its place near the top of the booming field of biotechnology. Today, Biogen looks more like prey than predator.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.